clinical trial · NCT07543276
Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
Opioid OverdoseNalmefene + 0.94% MgCl2Nalmefene + 0.94% MgCl2Nalmefene Hydrochloride Injection
brief summary
This study is designed to characterize the PK of nalmefene following IV bolus and IM injections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefene hydrochloride injection in healthy subjects.
started
Feb 6, 2026
primary completion
Apr 3, 2026
completion
Apr 3, 2026
last updated
Apr 24, 2026
official title
A Phase 1, Open Label, Randomized, Single Dose, Three-Period Crossover Study in Healthy Subjects to Compare the Pharmacokinetic Profiles of Nalmefene Following Administration of Intravenous and Intramuscular Nalmefene 0.5 mg (0.94% MgCl2) and Intravenous Nalmefene Hydrochloride Injection 0.5 mg
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol